Summary: Many patients suffering from major psychiatric disorders do not respond adequately to monotherapy and require additional drugs. To date, there are no objective guidelines for deciding which combination may be effective, and the choice is based on previous clinical experience and on trial and error. Even when combination drugs are effective, the biochemical mechanisms responsible for the value-added effect are unknown. Understanding the mechanism of such synergism may provide a rational basis for choosing drug combinations and for developing more effective drugs. In schizophrenia, negative symptoms respond poorly to antipsychotics, but may improve when these are augmented with selective serotonin reuptake inhibitors (SSRI). This augmenting effect cannot be explained by summating the pharmacological effects of the individual drugs. We proposed that the study of SSRI augmentation can serve as a window to understanding the biochemical mechanisms of clinically effective drug synergism. In a series of studies we identified unique biochemical effects of the combination, different from each individual drug, and proposed that some of these are involved in mediating the clinical effect. Here we review some of the findings and propose that the mechanism of action involves regionally selective modulation of the GABA system. The evidence indicates that the SSRI antidepressant-antipsychotic combination may be a useful paradigm for studying therapeutically effective synergistic drug interactions in schizophrenia. Although as yet limited in scope, the findings of definable molecular targets for synergistic SSRIantipsychotic interaction provide new directions to inform future research and provide novel bio-molecular targets for drug development.
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AUGMENTATION STRATEGIES IN PSYCHIATRIC DISORDERS
Psychiatric disorders such as schizophrenia, affective disorder, and obsessive compulsive disorder, are characterized by a wide range of behavioral, emotional, and cognitive abnormalities that often do not resolve completely with treatment.
1-3 Development of new drugs over the last few decades has not produced dramatic improvement in response of schizophrenia, as highlighted recently by findings of large comparative studies. 4, 5 Negative and cognitive symptoms of the illness have proved particularly resistant to treatment. In clinical practice, this often results in the use of more than one drug and, over the years, many combinations of psychotropics have been tried in an attempt to improve response. There is evidence that some combinations do induce a favorable clinical response not achieved by each of the drugs given alone, in some patients, 2, 3, 6, 7 but the choice of drug combinations and indications for their use are based on a trial-and-error paradigm guided by clinical experience and response.
Thus, there are empirical as well as theoretical reasons to think that single-action "magic bullets" may not be sufficient to treat complex neuropsychiatric diseases such as schizophrenia, and that multifunctional drugs or drug combinations that can simultaneously modify a number of CNS targets may be more effective. Better understanding of the biological principles by which combined treatments produce value-added effects can provide a rational basis for selection of appropriate drugs, as well as providing insights into the pathological mecha-nisms of the disorders. In this review, we examine some recent studies of SSRI augmentation of antipsychotics that have been demonstrated in controlled clinical trails to ameliorate negative symptoms in schizophrenia, and we examine their potential to serve as windows to understanding the molecular mechanisms underlying synergistic drug interactions in treatment of schizophrenia and other psychiatric disorders.
SELECTIVE SEROTONIN REUPTAKE INHIBITOR-ANTIPSYCHOTIC THERAPY FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
Schizophrenia is a chronic, disabling brain disorder that affects some 1% of the population worldwide and places a severe burden on the sufferer, the family, and society. The symptoms can be divided into two groups: positive symptoms (e.g., hallucinations and delusions) and negative symptoms (e.g., apathy, anhedonia, flat affect, avolition, and social withdrawal). Negative symptoms in particular are a challenge to available treatments. Antidopaminergic drugs, the mainstay of antipsychotic treatment, are usually effective against positive symptoms but not against negative symptoms; the success of newer generation, atypical drugs is also limited. 5, 8 A number of studies have demonstrated that adding SSRI antidepressants to antipsychotics can improve negative symptoms resistant to antipsychotic alone. Improvement was noted in controlled studies in patients treated with SSRI added to typical antipsychotics 9 -12 and in open studies and case reports on SSRI augmentation of atypical drugs (clozapine and olanzapine). [13] [14] [15] [16] 18 The response is in negative symptoms primary to the illness, 19 requires a serotonergic mechanism, 12 and can be detected within 2 weeks of starting augmentation. 20 The mechanism of SSRI augmentation is unknown. Several SSRI antidepressants inhibit cytochrome P-450 enzymes, mainly CYP1A2 and CYP2D6 isozymes, which are metabolizers of antipsychotic drugs. [21] [22] [23] Adding an SSRI antidepressant drug often results in an increase in plasma levels of the antipsychotic, 24, 25 which could underlie the superior efficiency of the augmentation treatments. However, improvement in negative symptoms of schizophrenic patients treated with SSRI and haloperidol did not correlate with the increase of antipsychotic levels in plasma. 26, 27 Increasing antipsychotic drug levels does not increase the overall efficacy or the range of responsive symptoms, and may have adverse effects. 28 -30 Antidepressant doses used in antidepressant-antipsychotic combinations are usually lower than those used in monotherapy. 7 Augmentation with SSRIs 24, 25, 31 or other drugs [32] [33] [34] that have no pharmacokinetic interactions with antipsychotics can also be effective in schizophrenia patients. Thus, pharmacokinetic interactions cannot explain the clinical efficacy of SSRI augmentation strategies for negative symptoms in schizophrenia.
The contribution of SSRI drugs as augmentation agents for treatment of negative symptoms appears to be distinct from nonspecific antidepressant action. First, in several controlled clinical studies, patients with prominent depressive symptoms were excluded and depression scale scores of participants were low and did not change following augmentation treatment. 7 Second, tricyclic antidepressants, which are equally effective antidepressants, do not improve negative symptoms in schizophrenic patients, although they can be useful when depression is associated with the disease. 35 Notably, SSRIs (which acts through serotonergic receptors), but not maprotiline (which acts via noradrenergic receptors), are effective augmentation agents for negative symptoms, 12 which suggests that the mechanism requires modification of the serotonergic system. 35 Paradoxically, clozapine and fluvoxamine-haloperidol combination produce a similar clinical effect, despite their different pharmacology: clozapine is a 5-HT antagonist and fluvoxamine elevates 5-HT concentration. Furthermore, adding SSRI to clozapine may improve effectiveness. 16, 17 Thus, the mechanisms mediating the clinical effects are likely to be located downstream from the initial pharmacological effects of the drugs at the receptor-transporter levels.
THE SSRI-ANTIPSYCHOTIC COMBINATION AS A PARADIGM FOR INVESTIGATING DRUG-DRUG SYNERGISM
Several characteristics of the SSRI antidepressant-antipsychotic combination make it a useful paradigm for studying therapeutically effective synergistic drug interactions in schizophrenia. First, the clinical effect is specific for a particular subset of clinical symptoms (negative symptoms), one that constitutes a core dimension of the illness, 1,36 with a response detectable within 2 weeks. Second, it is dependent on serotonergic action of the SSRI but not due to a general antidepressant effect. Third, the molecular mechanisms cannot be explained by the known actions of the individual drugs. Indeed, the fact that both clozapine, a serotonergic antagonist, and SSRI, a serotonin agonist, are effective is paradoxical, and although the pharmacological properties predict that combining clozapine with SSRI will lead to antagonism, clinical studies show that effectiveness may be improved. 9, 37 To account for these characteristics, we hypothesized that chronic treatment with the SSRI-antipsychotic combination produces unique biochemical changes in the brain, different from those of the individual drugs, and that these mediate the enhanced clinical effectiveness. 37 We argued that molecular changes unique to the drug combination and different from the action of individual drugs encompass those changes that are relevant to clinical effectiveness of the combined treatment and to the psychopathology of negative symptoms. We further argued that, by comparing the changes unique to the combination to those caused by clozapine, a chemically distinct drug also effective against negative symptoms, we could further narrow the focus on the molecular changes relevant to the clinical efficacy against negative symptoms. We argued that this clinically effective treatment could serve as the guiding framework to help identify clinically relevant molecular changes in the laboratory and provide a novel paradigm to study molecular mechanisms relevant to schizophrenia.
MOLECULAR MECHANISMS OF SSRI-ANTIPSYCHOTIC SYNERGISM
From this perspective, we investigated the effects of SSRI-antipsychotic combination on molecular systems in the rat brain. We chose fluvoxamine, the SSRI most frequently studied in clinical trials, and haloperidol, the classic antidopaminergic antipsychotic, as the study drugs. The standard experiment compared five groups: fluvoxamine and haloperidol, haloperidol alone, fluvoxamine alone, vehicle, and clozapine. Because the clinical effect is not immediate, we concentrated on chronic (30 days) and subchronic (14 days) administration and examined several brain regions including frontal cortex, striatum, and hippocampus.
Monoamine systems
Chronic administration of haloperidol plus fluvoxamine produced unique changes in dopaminergic and serotonergic metabolism in the rat brain, not shared by the individual drugs. 38 The effects were regionally selective and included areas known to be relevant to schizophrenia pathology. For example, haloperidol combined with fluvoxamine reduced dopamine turnover in the cerebellum, an area implicated in the pathophysiology of schizophrenia. 39 Notably, clozapine showed a similar effect. The combined haloperidol and fluvoxamine treatment increased dopamine metabolites and tyrosine hydroxylase protein level in the striatum when measured 1.5 hours after the last dose of chronic (30 days) treatment. 38 The effect of the combined treatment on dopamine metabolism was significantly greater than that of haloperidol alone and only in the combined group was this associated with changes in tyrosine hydroxylase protein levels. The authors interpreted this as indicating that adding fluvoxamine modulates the effect of haloperidol on dopamine metabolism. Because, like other SSRIs, fluvoxamine does not block dopaminergic receptors, 40 inhibit MAO activity, 41 or directly affect dopamine turnover, 38, 42, 43 it is likely that, when combined with haloperidol, fluvoxamine modifies dopamine pathways indirectly, perhaps via the serotonergic system. 44 These effects appear to depend on chronic administration, given findings from acute studies of increased dopamine release in rat prefrontal cortex after 5-HT uptake inhibitors combined with haloperidol, an effect not produced by the individual drugs, [45] [46] [47] [48] but no change in dopamine metabolism 49, 50 in the striatum.
GABA system
In a chronic (30 days) administration study, Chertkow et al. 51 used cDNA arrays to screen a broad range of genes in the frontal cortex. Prominent alterations were then analyzed in real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and their related proteins examined by the Western-blotting technique. The gene expression profile after fluvoxamine plus haloperidol administration was different from that of fluvoxamine or haloperidol given alone. Notably, clozapine showed some homology with the combined treatment. The protein expression changes unique to the combined treatment included glutamic acid decarboxylase (GAD 67 ) and protein kinase C␤ (PKC␤). The latter showed a similar trend following clozapine treatment. These findings support the hypothesis that SSRI-antipsychotic combination produces unique changes, different from those due to the individual drugs, and suggests that the mechanism of action may involve modification of the gamma aminobutyric acid (GABA) system. 51 Further studies in which the medications were administered for 14 days also supported this hypothesis. The combination of fluvoxamine and haloperidol resulted in unique changes in several elements of the GABA system in the rat frontal cortex, including GABA A R␤3, GAD 67 , PKC␤2, and ERK, which differed from the effect of each drug given alone (Danovich et al. 52 and unpublished data).
The unique molecular changes observed following combined treatment could not be explained by pharmacokinetic interactions, given that the concentrations of haloperidol and fluvoxamine in the brain and serum of the treated animals were similar whether the drugs were administered alone or in combination. 38 The observed molecular differences between treatment groups appeared in parallel with changes in overt behavior. Behavioral assessment performed a day before the animals were euthanized for post mortem analysis showed that animals in the haloperidol plus fluvoxamine group differed in motor activity and social behavior (sniffing) from those administered haloperidol or fluvoxamine alone. 38 The authors interpreted this as support for the view that changes observed in the brain may have functional significance.
GABA HYPOTHESIS OF SSRI-ANTIPSYCHOTIC AUGMENTATION
Based on these and other findings, we hypothesize that the molecular signaling pathways that regulate GABA receptor function (e.g., protein kinases C and A [PKC, PKA] and mitogen activated protein kinase [MAPK]) modify reciprocal interactions among dopamine, serotonin, and GABA neurotransmission and that their modulation mediates the clinical effect of SSRI augmentation on negative symptoms. The effect is localized to the prefrontal cortex (or it circuits) and is relevant to negative symptoms and (perhaps) cognitive impairments. It is further proposed that different mechanisms are responsible for the therapeutic effect on positive symptoms.
CLINICAL RELEVANCE
The relevance of laboratory findings and consequent hypotheses to the clinical situation requires independent validation in patients. One way to examine this is to study expression of gene products and proteins in blood cells of patents undergoing augmentation treatment. Peripheral mononuclear cells may reflect molecular processes in the CNS of schizophrenic patients and have been used to study various substances including cytokines (e.g., interleukins IL-6, IL-10, and IL-2), receptors for major neurotransmitters (e.g., dopamine, serotonin, and GABA A ), and G-protein subunits that regulate intracellular signal transduction. [53] [54] [55] [56] [57] [58] [59] [60] [61] Chertkow et al. 62 used microarrays to examine the gene expression profile of peripheral mononuclear cells in schizophrenia patients on steady antipsychotic treatment before and 3 and 6 weeks after addition of fluvoxamine and found changes in transcripts related to Gprotein coupled receptors. Using customized cDNA array and real-time RT-PCR, they also found significant downregulation of chemokine receptors IL8RA and CCR1, and of RGS7 mRNA. Notably, these changes paralleled improvement in negative symptoms. Several of the peripheral mononuclear cell genes that changed in the course of augmentation treatment have been reported to be abnormally expressed in post mortem brains of schizophrenia patients. These include genes for the 5-HT2A receptor, 63 IL-1 receptor antagonist, 64 RGS7, 65, 66 and the neural specific protein neurogranin. 67 Although one must keep in mind the limitation of using peripheral changes as indicators of brain processes, these findings nonetheless support the view that these laboratory findings may have clinical validity.
The hypothesis that SSRI-haloperidol augmentation acts by modulating GABA system is consistent with accumulating evidence of GABA system abnormalities in schizophrenia. Post mortem studies show loss of specific GABAergic inhibitory neurons, 68 reduction in the GABA synthesizing enzyme (GAD 67 ) 69 -72 , and compensatory upregulation of the GABA A receptor 73, 74 in brains of schizophrenia patients. In addition, hypofunction of the ionotropic glutamate NMDA receptor 75 and its modification 76 may play an important role in the pathophysiology and treatment of negative symptoms, respectively, and lead to inhibition of GABAergic interneurons. 77 GABA plays a key role in the function of the prefrontal cortex, an area impaired in schizophrenia 78 and linked to negative symptoms and cognitive impairment, 79, 80 including working memory, a core cognitive deficit in the illness. 81 Antipsychotic drugs can modify GABA and glutamate system elements, including GABA A receptor, extracellular GABA levels and expression, glutamate transporters, 82 and neuregulin-1 (which regulates the expression of NMDA and GABA A receptors), 83 as well as ionotropic and metabotropic glutamate receptors. 84, 85 Interestingly, atypical antipsychotics differ from the typical ones in their effect on the GABA system, including hippocampal and cortical GABA A receptor density, 86 GABA transporter expression, 87 and GABA transporter levels. 88 Mechanisms that may mediate drug-induced modification of the GABA system include inhibition of dopamine innervations on GABA and glutamate neurons, activation of PKC anchored to Rack1 (which then phosphorylates GABA A receptor), 89 and increase in brain levels of allopregnanolone, a potent positive allosteric modulator of GABA at the GABA A receptor. 90 Several of these elements showed unique changes following combined SSRI-antipsychotic treatment.
There is clinical evidence linking GABA/glutamate active agents with negative and cognitive symptoms in schizophrenia. Silver et al. 91 found significant correlations between blood levels of dehydroepiandrosterone in its sulfated form (DHEAS) levels and cognitive function in schizophrenia patients. Augmentation with DHEA 92 or agonists at glycine sites 93, 94 have been reported to improve negative symptoms in schizophrenic patients maintained on antipsychotic drugs, excluding clozapine. 95 Drugs modulating GABA activity can differentially affect working memory performance and brain function in schizophrenia. 96 Further clinical support for the relevance of GABA function for negative symptoms and cognitive functions comes from a study examining the relationship between visuomotor performance, working memory and negative symptoms. GABA neurotransmission within the dorsolateral prefrontal cortex is critical for normal working memory function, 97, 98 goal maintenance, and interference control. 99 In a series of studies examining the relationships between diverse cognitive processes and functions, Silver et al. 100, 101 reported a strong association between the ability to resist distraction on a visuomotor task and verbal working memory in schizophrenia patients and interpreted this as reflecting shared prefrontal cortex attention mechanisms. The ability to resist distraction in the visuomotor task was also associated with negative (but not positive) symptoms, 101 suggesting that negative symptoms also share these attention resources. Given the important role of GABA in goal maintenance and interference control, these findings support the view that GABA plays a functional role in negative and cognitive symptoms of schizophrenia. One prediction of our hypothesis then is that GABA system modification by SSRI-antipsychotic combination may improve cognitive impairment in schizophrenia. This is currently under investigation.
CLINICAL IMPLICATIONS
Accumulating evidence supports the view that SSRI augmentation of antipsychotics is a useful treatment addition, and that studying its mechanism can serve as a window to understanding the mechanisms of synergism in schizophrenia. The findings in animal studies that SSRI-antipsychotic combinations produced unique effects support the view that specific pathways are modulated, and the findings that modulation involves the GABA system are consistent with clinical findings. Evidence that patients treated with SSRI-antipsychotic combination show changes in peripheral mononuclear cells consistent with those of animal studies and include proteins that are found in the brain (e.g., neurogranin) is encouraging and provides some, albeit limited, indication that the laboratory findings may have clinical relevance. Clearly, the preliminary nature of the data must be emphasized and many questions remain to be addressed in future studies. At the molecular level it will be necessary to identify the precise sequences by which the drugs interact to alter PKC and other GABA modulators, and how they interact with other neurotransmitter and cell signaling systems that also show unique responses to the combination treatment.
At the clinical level, studies will need to determine, among other questions, whether the mechanisms relevant for negative symptom amelioration also apply to other conditions that respond to SSRI-antipsychotic combination, such as resistant obsessive-compulsive disorders and depression, and whether particular combinations of SSRIs and antipsychotics differ in efficacy or show selectivity for particular clinical symptom profiles.
FINAL COMMENTS AND FUTURE PERSPECTIVES
Negative symptoms in schizophrenia, like other treatment-resistant symptoms of psychiatric illnesses, continue to be therapeutic challenges despite several decades of new drug development. Clearly, new paradigms and new molecular targets are needed to develop novel and more effective pharmacotherapeutic compounds. Given the complexity of the conditions, it is unlikely that single-action drugs given alone will be effective, and therefore a multifunctional approach, as in augmentation treatment, may be needed.
We have argued that the SSRI-antipsychotic combination provides a novel paradigm that can advance understanding of the multifunctional mechanisms responsible for complex clinical phenotypes. The studies described here support the view that SSRI-antipsychotic combination produces unique molecular changes in the brain, changes that differ from those seen with the individual drugs. These changes are localized anatomically, and involve systems at various cellular levels, downstream from the initial impact of the drugs on membrane receptors or transporters. They modify widespread pathways and cellular processes, such as rate of neurotransmission, connectivity, plasticity, and proliferation.
We have highlighted some of the systems which current evidence suggests may provide plausible molecular meeting points for actions of pharmacologically distinct treatments and may underlie their convergent clinical effects. Clearly, the available data are limited, and much research is needed to identify and validate the molecular targets of SSRI-antipsychotic and other augmentation treatments. Conceptually, the method of isolating molecular effects of pharmacologically distinct but clinically convergent drugs provides a useful window for an understanding of the mechanisms of multifunctional treatments and development of new more effective drugs.
